 P106 Overview | AstraZeneca at a glance AstraZeneca Annual Report and Form 20-F Information 2012 2 We are a global, innovation-driven   biopharmaceutical business Financial summary $27 .97bn Sales down 15% at CER to $27 ,973 million  ($33,591 million in 2011) $1 0.4bn Core operating proﬁt down 18% at CER   to $10,430 million ($13,167 million in 2011) $8. 1bn Reported operating proﬁt down 34%   at CER to $8,148 million ($12,795 million   in 2011) $6.41 Core EPS for the full year decreased   by 9% at CER to $6.41 ($7 .28 in 2011) $4.99 Reported EPS for the full year decreased   by 29% at CER to $4.99 ($7 .33 in 2011)  $5.9bn Net cash shareholder distributions  decreased by 37% to $5,871 million  including net share repurchases   of $2,206 million ($9,370 million net   cash shareholder distributions   including $5,606 million net share  repurchases in 2011) $10,655m  Regional sales US (-21%)   14,400 *   employees in the Americas (27 .9%)  30,200 *   Sales and Marketing employees: numbers  in Established Markets, such as the US,  have fallen, whereas the numbers in  Emerging Markets have increased and  now represent 53% of the total Our medicines Our 10 leading medicines by sales value are: Atacand  for hypertension   and heart failure   2010: $1,483m  2011: $1,450m  Crestor  for managing  cholesterol levels   2010: $5,691m 2011: $6,622m  Seloken/Toprol-XL  for hypertension, heart  failure and angina  2010: $1,210m 2011: $986m  Synagis  for RSV, a respiratory  infection in infants   2010: $1,038m 2011: $975m  2012 $1 ,009m  (-27%) 2012 $6,253m  (-4%) 2012 $918m (-4%) 2012 $3,944m (-10%) 2012 $1 ,038m  (+6%) Cardiovascular Infection Gastrointestinal Our primary focus is the discovery, development and commercialisation of prescription  medicines for six important areas of healthcare: Cardiovascular, Gastrointestinal, Infection,  Neuroscience, Oncology and Respiratory & Inﬂammation.  We operate in over 100 countries and our innovative medicines are used by millions   of patients worldwide. We are one of only a handful of companies to span the entire  life-cycle of a medicine from discovery, early and late-stage development, to the global  commercialisation of primary care, specialty care-led and specialty care medicines. Using  these skills and capabilities we can make a real difference to the health of a broad range of  patients by delivering great medicines in disease areas where there is unmet medical need. We want AstraZeneca to be valued as a source of great medicines and trusted as a  company that delivers business success responsibly. Our Responsible Business Plan  provides the framework for ensuring that we operate with integrity and high ethical  standards across all our activities. Nexium  for acid-reﬂux     2010: $4,969m 2011: $4,429m  2012 $3,944m  (-10%) AstraZeneca Annual Report and Form 20-F Information 2012 3 Overview Strategy Performance Corporate Governance Financial Statements Additional Information $6,486m  Regional sales Western Europe (-19%) 51, 700 *   employees worldwide $5,080m  Regional sales Established ROW (- 14%) 9,800 * employees work in our R&D organisation  and we have 10 principal R&D centres   in six countries $5,752m  Regional sales Emerging Markets (+4%)  13, 700 *   employees in Asia Paciﬁc (26.5%)   10,300 *   employees work at our 22 Supply and  Manufacturing sites in 16 countries  Seroquel IR  for schizophrenia   and bipolar disorder   2010: $4,148m  2011: $4,338m Seroquel XR  for schizophrenia, bipolar  disorder and major  depressive disorder 2010: $1,154m 2011: $1,490m  Zoladex  for prostate   and breast cancer   2010: $1,115m 2011: $1,179m  Pulmicort  for asthma and chronic  obstructive pulmonary  disease  2010: $872m 2011: $892m  2012 $1,294m  (-70%) 2012 $1 ,509m  (+4%) 2012 $1,093m  (-5%) 2012 $866m  (-1%) Neuroscience Oncology Symbicort  for asthma and chronic  obstructive pulmonary  disease  2010: $2,746m 2011: $3,148m  2012 $3, 194m  (+5%) Respiratory & Inﬂammation 23,600 *   employees in EMEA (45.6%) * All ﬁgures are approximate. Overview | AstraZeneca at a glance AstraZeneca Annual Report and Form 20-F Information 2012 4 Financial overview 12 27,973 11 33,591 10 33,269 Sales  $m (-15%) 12 6,948 11 7,821 10 10,680 Net cash ﬂow from   operating activities $m 12 8,148 11 12,795 10 11,494 Reported operating proﬁt  $m (-34%) 12 14,882 11 18,200 10 17,822 Core pre-R&D operating proﬁt $m (-16%) 12 13,391 11 18,318 10 16,812 Reported pre-R&D   operating proﬁt $m (-25%) 84 pipeline projects 88 countries 11% reduction in R&D  expense 15% reduction in revenue $4.5bn loss of exclusivity  reduction Pipeline Deliver the business >  84 pipeline projects  including 71 in clinical  development, of which   11 are in Phase III or  under regulatory review;   19 withdrawn during  the year  > Brilinta/Brilique has  been approved in 88  countries, launched   in 82 countries and  remains under review   in 23 countries.   Global sales of   $89 million in 2012 >    Core R&D expense for  the full year was down  11%, despite absorbing  higher costs from  spending on in-licensed,  acquired or partnered  projects, as these were  more than offset by  restructuring beneﬁts  and lower intangible  impairments than   in 2011 >  Revenue fell by 21% in  the US; 19% in Western  Europe; and 14% in  Established Rest of  World. Revenue rose by  4% in Emerging Markets >  Some $4.5 billion of  revenue decline was 